Alvotech and Teva have confirmed that their AVT04 proposed Stelara (ustekinumab) biosimilar has been accepted for filing by the US Food and Drug Administration, ahead of the blockbuster biologic brand’s US composition of matter patent expiring later this year.
“The companies anticipate that the FDA’s review will be completed in the second half of 2023,” Alvotech indicated.






